A Metanalysis of Parkinson's Disease

Authors

  • Sarah Wang Polygence
  • Emily Polygence

DOI:

https://doi.org/10.47611/jsrhs.v13i2.6730

Keywords:

Parkinson's Disease, Metanalysis, Environmental Factors, COVID-19 Impact, Socioeconomic, Genetics

Abstract

Parkinson's disease is one of the most prominent and devastating neurodegenerative disorders worldwide. However, each PD patient has a unique disease course due to individual variations in the rate of cognitive and psychomotor decline. In this review article, we will analyze factors influencing such individual variation and the amount of concrete information we currently have on PD. We will focus particularly on genetic factors, social/socioeconomic factors, and medical comorbidities using existing data and information gathered from previous experiments. We will discuss the implications such factors should have on treatment options and disease management and the effects the COVID-19 pandemic had on PD patients.

Downloads

Download data is not yet available.

Author Biography

Emily, Polygence

My name is Emily, and I'm a medical resident at UC San Diego pursuing neuroradiology. I graduated from Yale School of Medicine in May 2023 and previously was a Neuroscience major at Princeton. I'm passionate about neuroscience, neuroimaging, and the impact that AI can have on these fields. My current area of research focuses on applying AI/ML techniques to improve stroke patient outcomes based on their admission CT imaging data. 

References or Bibliography

Statistics | Parkinson’s Foundation. Accessed November 12, 2023. https://www.parkinson.org/understanding-parkinsons/statistics

Sonne J, Reddy V, Beato MR. Neuroanatomy, Substantia Nigra. In: StatPearls. StatPearls Publishing; 2023. Accessed October 1, 2023. http://www.ncbi.nlm.nih.gov/books/NBK536995/

Australia H. Dopamine. Published November 6, 2023. Accessed November 12, 2023. https://www.healthdirect.gov.au/dopamine

Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet. 2023;68(3):125-130. doi:10.1038/s10038-022-01058-5

Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease: Genetics and Cognition in PD. Mov Disord. 2012;27(4):512-518. doi:10.1002/mds.24946

Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol. 2009;256(3):493-498. doi:10.1007/s00415-009-0119-8

Hoehn and Yahr Scale. Physiopedia. Accessed November 12, 2023. https://www.physio-pedia.com/Hoehn_and_Yahr_Scale

Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s Disease and the Environment. Front Neurol. 2019;10. Accessed October 1, 2023. https://www.frontiersin.org/articles/10.3389/fneur.2019.00218

Langston JW. The MPTP Story. J Park Dis. 2017;7(s1):S11-S19. doi:10.3233/JPD-179006

MAO-B Inhibitors | Parkinson’s Foundation. Accessed October 1, 2023. https://www.parkinson.org/living-with-parkinsons/treatment/prescription-medications/mao-b-inhibitors

Pyatha S, Kim H, Lee D, Kim K. Association between Heavy Metal Exposure and Parkinson’s Disease: A Review of the Mechanisms Related to Oxidative Stress. Antioxidants. 2022;11(12):2467. doi:10.3390/antiox11122467

Cheng P, Yu J, Huang W, et al. Dietary intake of iron, zinc, copper, and risk of Parkinson’s disease: a meta-analysis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2015;36(12):2269-2275. doi:10.1007/s10072-015-2349-0

Meamar R, Nikyar H, Dehghani L, Basiri K, Ghazvini MRA. Assessing of plasma levels of iron, zinc and copper in Iranian Parkinson’s disease. Adv Biomed Res. 2016;5(1):31. doi:10.4103/2277-9175.178788

Costa-Mallen P, Gatenby C, Friend S, et al. Brain Iron Concentrations in Regions of Interest and Relation with Serum Iron Levels in Parkinson Disease. J Neurol Sci. 2017;378:38-44. doi:10.1016/j.jns.2017.04.035

Contributors WE. What Is Oxidative Stress? WebMD. Accessed October 21, 2023. https://www.webmd.com/a-to-z-guides/what-is-oxidative-stress

Weiss Annulation - an overview | ScienceDirect Topics. Accessed October 1, 2023. https://www.sciencedirect.com/topics/chemistry/weiss-annulation

Protein Aggregation - an overview | ScienceDirect Topics. Accessed October 1, 2023. https://www.sciencedirect.com/topics/neuroscience/protein-aggregation

Brooks SK, Weston D, Greenberg N. Social and psychological impact of the COVID-19 pandemic on people with Parkinson’s disease: a scoping review. Public Health. 2021;199:77-86. doi:10.1016/j.puhe.2021.08.014

Shalash A, Roushdy T, Essam M, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID ‐19 Pandemic. Mov Disord. 2020;35. doi:10.1002/mds.28134

Exercise | Parkinson’s Foundation. Accessed February 18, 2024. https://www.parkinson.org/living-with-parkinsons/treatment/exercise

How Stress and Stress Management Impact Parkinson’s | Parkinson’s Foundation. Published November 16, 2021. Accessed January 28, 2024. https://www.parkinson.org/blog/how-stress-and-stress-management-impact-parkinsons

Feeney MP, Xu Y, Surface M, et al. The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study. Npj Park Dis. 2021;7(1):10. doi:10.1038/s41531-020-00153-8

Bulkes NZ, Davis K, Kay B, Riemann BC. Comparing efficacy of telehealth to in-person mental health care in intensive-treatment-seeking adults. J Psychiatr Res. 2022;145:347-352. doi:10.1016/j.jpsychires.2021.11.003

Fearon C, Fasano A. Parkinson’s Disease and the COVID-19 Pandemic. J Park Dis. 2021;11(2):431-444. doi:10.3233/JPD-202320

Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy. Mov Disord Off J Mov Disord Soc. 2020;35(7):1089-1093. doi:10.1002/mds.28176

Artusi CA, Romagnolo A, Imbalzano G, et al. COVID-19 in Parkinson’s disease: Report on prevalence and outcome. Parkinsonism Relat Disord. 2020;80:7-9. doi:10.1016/j.parkreldis.2020.09.008

McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. Front Public Health. 2020;8:231. doi:10.3389/fpubh.2020.00231

Okoro CA, Strine TW, Young SL, Balluz LS, Mokdad AH. Access to health care among older adults and receipt of preventive services. Results from the Behavioral Risk Factor Surveillance System, 2002. Prev Med. 2005;40(3):337-343. doi:10.1016/j.ypmed.2004.06.009

NIMH » What is Prevalence? Accessed November 11, 2023. https://www.nimh.nih.gov/health/statistics/what-is-prevalence

Schapira AHV. Parkinson’s disease. BMJ. 1999;318(7179):311-314.

Parkinson’s Disease – Symptoms, Diagnosis and Treatment. Accessed October 1, 2023. https://www.aans.org/

Pedrosa DJ, Timmermann. Review: management of Parkinson's disease. Neuropsychiatr Dis Treat. Published online March 2013:321. doi:10.2147/NDT.S32302

Levodopa and the Progression of Parkinson’s Disease. N Engl J Med. 2004;351(24):2498-2508. doi:10.1056/NEJMoa033447

Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol. 2017;13(11):689-703. doi:10.1038/nrneurol.2017.128

Rahimpour S, Gaztanaga W, Yadav AP, et al. Freezing of Gait in Parkinson’s Disease: Invasive and Noninvasive Neuromodulation. Neuromodulation J Int Neuromodulation Soc. 2021;24(5):829-842. doi:10.1111/ner.13347

Published

05-31-2024

How to Cite

Wang, S., & Avery, E. (2024). A Metanalysis of Parkinson’s Disease. Journal of Student Research, 13(2). https://doi.org/10.47611/jsrhs.v13i2.6730

Issue

Vol. 13 No. 2 (2024)

Section

HS Review Articles

Copyright (c) 2024 Sarah Wang; Emily

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.